Zealand Pharma starts Phase 3 ZUPREME programme for petrelintide

The Copenhagen biotech and Roche partner have initiated three placebo-controlled trials enrolling around 7,000 participants across obesity sub-populations.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit operating room contains a surgical table, two large overhead lights, medical monitors, IV stands, and instrument trays covered with blue drapes on mobile carts, set against large windows.

Zealand Pharma has initiated its registrational Phase 3a ZUPREME programme for petrelintide, a once-weekly amylin analogue being co-developed with Roche for chronic weight management. The programme, announced on 22 September 2026, comprises three large randomised, double-blind, placebo-controlled trials that together aim to enrol approximately 7,000 participants across distinct obesity sub-populations.

The Phase 3 launch follows Phase 2 results that the company says demonstrated double-digit percentage weight loss with a tolerability profile broadly comparable to placebo. Zealand has not released the full Phase 2 dataset publicly in this announcement, so the precise magnitude of weight reduction and safety detail remain to be scrutinised in peer-reviewed form.

The three trials

ZUPREME-3 is the largest arm, targeting around 3,900 participants with overweight or obesity (BMI of 27 or above) who do not have type 2 diabetes (T2D) but carry at least one weight-related comorbidity. ZUPREME-4 will enrol roughly 600 participants with overweight or obesity and confirmed T2D. ZUPREME-5, the cardiovascular outcomes arm, will enrol approximately 2,500 participants with established cardiovascular disease, with or without T2D, and can run for up to three years.

All three trials follow a 12-week dose-escalation period and a maintenance phase, with the primary efficacy assessment at week 64, measuring percentage change in body weight from baseline. Secondary endpoints include waist circumference, HbA1c, cardiometabolic risk factors, physical functioning, and eating behaviour change. Participants completing ZUPREME-3 and ZUPREME-4 will be offered entry into an open-label extension study.

David Kendall, Chief Medical Officer at Zealand Pharma, said the programme is "designed to generate the robust, longer-term evidence needed to support regulatory filings and bring petrelintide to the millions of people demanding a better weight management experience."

Market context and competitive positioning

The global obesity therapeutics market is intensely contested. Semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) have established GLP-1 receptor agonism as the dominant mechanistic class, each commanding significant and growing commercial share. Petrelintide operates via a different biology: amylin receptor activation is thought to restore sensitivity to the satiety hormone leptin, inducing earlier satiety rather than primarily slowing gastric emptying. Zealand and Roche are positioning this differentiated mechanism as potentially more tolerable than GLP-1-based agents, a claim that the ZUPREME programme will need to substantiate at scale.

A separate Phase 2 trial combining petrelintide with Roche's dual GLP-1/GIP receptor agonist enicepatide is planned for the second half of 2026, pointing to a broader strategic ambition to field both a standalone product and a combination therapy. The collaboration, struck in 2025, gives Roche co-commercialisation rights alongside Zealand's peptide design expertise, which spans more than 25 years of proprietary peptide R&D.

Regulatory precedent from the semaglutide and tirzepatide approvals gives the field a reasonably clear blueprint for what the FDA and EMA expect from obesity registrational programmes: weight loss superiority over placebo, cardiovascular safety data, and evidence of durable effect. ZUPREME-5's cardiovascular arm appears designed directly to meet that last requirement, and its potential duration of up to three years signals an intent to pursue a broad label.

Near-term milestones for investors and clinicians to watch include interim data readouts from ZUPREME-3 and ZUPREME-4, the initiation of the petrelintide-enicepatide combination Phase 2 trial, and the full publication of Phase 2 monotherapy results in a peer-reviewed journal.

Sector

Topic

Geography